Early diagnosis of pancreatic cancer: Challenges and new developments

Biomarkers in Medicine

Volumn 6, Issue 5, 2012, Pages 597-612

  Kaur, Sukhwinder ^a   Baine, Michael J ^b   Jain, Maneesh ^a   Sasson, Aaron R ^a   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

autoantibody; circulating tumor cell; imaging; pancreatic cancer; serological marker; tumor

Indexed keywords

AUTOANTIBODY; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CHEMOKINE; CYTOKINE; MICRORNA; MUCIN; MUCIN 16; MUCIN 5AC; UNCLASSIFIED DRUG;

AGE; ANTIBODY PRODUCTION; CANCER DIAGNOSIS; CANCER SCREENING; CHRONIC PANCREATITIS; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; DNA METHYLATION; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EPIGENETICS; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL CANCER; FAMILY HISTORY; HIGH RISK POPULATION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PEUTZ JEGHERS SYNDROME; POSITRON EMISSION TOMOGRAPHY; RACE DIFFERENCE; REVIEW; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SMOKING; SOMATIC MUTATION; SURVIVAL RATE;

EARLY DETECTION OF CANCER; GENETIC MARKERS; HUMANS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867646268     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.69     Document Type: Review

References (111)

1. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2009. National Cancer institute, MD, USA (2012).
2. Chu D, Kohlmann W, Adler DG. Identifcation and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP 11(3), 203-212 (2010).
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
4. Campbell PJ, Yachida S, Mudie LJ et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467(7319), 1109-1113 (2010).
5. Luebeck EG. Cancer: genomic evolution of metastasis. Nature 467(7319), 1053-1055 (2010).
6. Yachida S, Jones S, Bozic I et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319), 1114-1117 (2010).
7. Gangi S, Fletcher JG, Nathan MA et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am. J. Roentgenol. 182(4), 897-903 (2004). (Pubitemid 38391649)
8. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 6(4), 1186-1197 (2007). (Pubitemid 46711982)
9. Canto MI, Goggins M, Yeo CJ et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin. Gastroenterol. Hepatol. 2(7), 606-621 (2004). (Pubitemid 38834045)
10. Langer P, Kann PH, Fendrich V et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 58(10), 1410-1418 (2009).
11. Ludwig E, Olson SH, Bayuga S et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am. J. Gastroenterol. 106(5), 946-954 (2011).
12. Matsubayashi H, Fukushima N, Sato N et al. Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer. Cancer Biol. Ther. 2(6), 652-655 (2003).
13. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann. Intern. Med. 131(4), 247-255 (1999). (Pubitemid 29383653)
14. Canto MI, Goggins M, Yeo CJ et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin. Gastroenterol. Hepatol. 2(7), 606-621 (2004). (Pubitemid 38834045)
15. Canto MI, Goggins M, Hruban RH et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin. Gastroenterol. Hepatol. 4(6), 766-781 (2006). (Pubitemid 43825802)
16. McWilliams RR, Petersen GM, Rabe KG et al. Cystic fbrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer 116(1), 203-209 (2010).
17. Poley JW, Kluijt I, Gouma DJ et al. The yield of frst-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am. J. Gastroenterol. 104(9), 2175-2181 (2009).
18. Vasen HF, Wasser M, van Mil A et al. Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140(3), 850-856 (2011).
19. Huxley R, Ansary-Moghaddam A, Berrington de GA, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a metaanalysis of 36 studies. Br. J. Cancer 92(11), 2076-2083 (2005). (Pubitemid 40897433)
20. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 10(1), 88-95 (2009).
21. Chari ST, Leibson CL, Rabe KG et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134(1), 95-101 (2008). (Pubitemid 350309328)
22. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur. J. Surg. 159(2), 101-107 (1993). (Pubitemid 23112386)
23. Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. N. Engl. J. Med. 331(2), 81-84 (1994). (Pubitemid 24202222)
24. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur. J. Cancer 47(13), 1928-1937 (2011).
25. Aggarwal G, Rabe KG, Petersen GM, Chari ST. New-onset diabetes in pancreatic cancer: a study in the primary care setting. Pancreatology 12(2), 156-161 (2012).
26. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profle of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134(4), 981-987 (2008). (Pubitemid 351451984)
27. Zakharova OP, Karmazanovsky GG, Egorov VI. Pancreatic adenocarcinoma: outstanding problems. World J. Gastrointest. Surg. 4(5), 104-113 (2012).
28. Raut CP, Grau AM, Staerkel GA et al. Diagnostic accuracy of endoscopic ultrasound-guided fne-needle aspiration in patients with presumed pancreatic cancer. J. Gastrointest. Surg. 7(1), 118-126 (2003).
29. Gheonea DI, Saftoiu A. Beyond conventional endoscopic ultrasound: elastography, contrast enhancement and hybrid techniques. Curr. Opin. Gastroenterol. 27(5), 423-429 (2011).
30. Pan S, Chen R, Crispin DA et al. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profling. J. Proteome Res. 10(5), 2359-2376 (2011).
31. Chang TH, Steplewski Z, Sears HF, Koprowski H. Detection of monoclonal antibody-defned colorectal carcinoma antigen by solid-phase binding inhibition radioimmunoassay Hybridoma 1(1), 37-45 (1981). (Pubitemid 13214104)
32. Goggins M. Molecular markers of early pancreatic cancer. J. Clin. Oncol. 23(20), 4524-4531 (2005). (Pubitemid 46196582)
33. Yue T, Partyka K, Maupin KA et al. Identifcation of blood-protein carriers of the CA19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics 11(18), 3665-3674 (2011).
34. Yue T, Maupin KA, Fallon B et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA19-9 antigen on specifc protein carriers. PLoS One 6(12), e29180 (2011).
35. Partyka K, Maupin KA, Brand RE, Haab BB. Diverse monoclonal antibodies against the CA19-9 antigen show variation in binding specifcity with consequences for clinical interpretation. Proteomics 12(13), 2212-2220 (2012).
36. Hamanaka Y, Suehiro Y, Fukui M, Shikichi K, Imai K, Hinoda Y. Circulating anti- MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int. J. Cancer 103(1), 97-100 (2003). (Pubitemid 35424210)
37. Maacke H, Hundertmark C, Miska S, Voss M, Kalthoff H, Sturzbecher HW Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J. Cancer Res. Clin. Oncol. 128(4), 219-222 (2002). (Pubitemid 34280380)
38. Hong SH, Misek DE, Wang H et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 64(15), 5504-5510 (2004). (Pubitemid 39006575)
39. Tomaino B, Cappello P, Capello M et al. Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer. J. Proteome Res. 10(1), 105-112 (2011).
40. Hong SH, Misek DE, Wang H et al. Identifcation of a specifc vimentin isoform that induces an antibody response in pancreatic cancer. Biomark. Insights 1, 175-183 (2006).
41. Desmetz C, Mange A, Maudelonde T, Solassol J. Autoantibody signatures: progress and perspectives for early cancer detection. J. Cell Mol. Med. 15(10), 2013-2024 (2011).
42. Tomaino B, Cappello P, Capello M et al. Autoantibody signature in human ductal pancreatic adenocarcinoma. J. Proteome Res. 6(10), 4025-4031 (2007). (Pubitemid 350032566)
43. Bracci PM, Zhou M, Young S, Wiemels J. Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study. Cancer doi: 10.1002/cncr.27538 (2012) (Epub ahead of print).
44. Ingvarsson J, Wingren C, Carlsson A et al. Detection of pancreatic cancer using antibody microarray-based serum protein profling. Proteomics 8(11), 2211-2219 (2008). (Pubitemid 351898027)
45. Wingren C, Sandstrom A, Segersvard R et al. Identifcation of serum biomarker signatures associated with pancreatic cancer. Cancer Res. 72(10), 2481-2490 (2012).
46. Zeh HJ, Winikoff S, Landsittel DP et al. Multianalyte profling of serum cytokines for detection of pancreatic cancer. Cancer Biomark. 1(6), 259-269 (2005).
47. Grote VA, Kaaks R, Nieters A et al. Infammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br. J. Cancer 106(11), 1866-1874 (2012).
48. Pistol-Tanase C, Raducan E, Dima SO et al. Assessment of soluble angiogenic markers in pancreatic cancer. Biomark. Med. 2(5), 447-455 (2008).
49. Twine NC, Stover JA, Marshall B et al. Disease-associated expression profles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res. 63(18), 6069-6075 (2003). (Pubitemid 37187512)
50. Sun CJ, Zhang L, Zhang WY. Gene expression profling of maternal blood in early onset severe preeclampsia: identifcation of novel biomarkers. J. Perinat. Med. 37(6), 609-616 (2009).
51. Baine MJ, Chakraborty S, Smith LM et al. Transcriptional profling of peripheral blood mononuclear cells in pancreatic cancer patients identifes novel genes with potential diagnostic utility. PLoS One 6(2), e17014 (2011).
52. Baine MJ, Menning M, Smith LM et al. Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer. Cancer Biomark. 11(1), 1-14 (2011).
53. Rhim AD, Mirek ET, Aiello NM et al. EMT and dissemination precede pancreatic tumor formation. Cell 148(1-2), 349-361 (2012).
54. Greco FA, Hainsworth JD. Introduction: unknown primary cancer. Semin. Oncol. 36(1), 6-7 (2009).
55. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specifc biological properties of disseminating tumour cells. Nat. Rev. Cancer 8(5), 329-340 (2008). (Pubitemid 351596394)
56. de Albuquerque A, Kubisch I, Breier G et al. Multimarker gene analysis of circulating tumor cells in pancreatic cancer patients: a feasibility study. Oncology 82(1), 3-10 (2012).
57. Ren C, Han C, Zhang J et al. Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fuorouracil chemotherapy. Cancer Biol. Ther. 12(8), 700-706 (2011).
58. Yu M, Ting DT, Stott SL et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487(7408), 510-513 (2012).
59. Levenson V V, Melnikov AA. The MethDet: a technology for biomarker development. Expert Rev. Mol. Diagn. 11(8), 807-812 (2011).
60. Sato N, Fukushima N, Maitra A et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 63(13), 3735-3742 (2003). (Pubitemid 36793060)
61. Park JK, Ryu JK, Yoon WJ et al. The role of quantitative NPTX2 hypermethylation as a novel serum diagnostic marker in pancreatic cancer. Pancreas 41(1), 95-101 (2012).
62. Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 34(1), 55-62 (2007). (Pubitemid 46045721)
63. Shimizu H, Horii A, Sunamura M et al. Identifcation of epigenetically silenced genes in human pancreatic cancer by a novel method "microarray coupled with methyl-CpG targeted transcriptional activation" (MeTA-array). Biochem. Biophys. Res. Commun. 411(1), 162-167 (2011).
64. Melnikov AA, Scholtens D, Talamonti MS, Bentrem DJ, Levenson V V. Methylation profle of circulating plasma DNA in patients with pancreatic cancer. J. Surg. Oncol. 99(2), 119-122 (2009).
65. Liggett T, Melnikov A, Yi QL et al. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 116(7), 1674-1680 (2010).
66. Albulescu R, Neagu M, Albulescu L, Tanase C. Tissular and soluble miRNAs for diagnostic and therapy improvement in digestive tract cancers. Expert. Rev. Mol. Diagn. 11(1), 101-120 (2011).
67. Tomankova T, Petrek M, Kriegova E. Involvement of microRNAs in physiological and pathological processes in the lung. Respir. Res. 11, 159 (2010).
68. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol. 3(3), e85 (2005).
69. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often fanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120(1), 15-20 (2005). (Pubitemid 40094598)
70. Bueno MJ, Perez de Castro, I, Gómez de Cedrón M et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13(6), 496-506 (2008). (Pubitemid 351763902)
71. Lu J, Getz G, Miska EA et al. MicroRNA expression profles classify human cancers. Nature 435(7043), 834-838 (2005). (Pubitemid 40839735)
72. Szafranska AE, Davison TS, John J et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26(30), 4442-4452 (2007). (Pubitemid 47014466)
73. Ren Y, Gao J, Liu JQ et al. Differential signature of fecal microRNAs in patients with pancreatic cancer. Mol. Med. Report 6(1), 201-209 (2012).
74. Yu J, Li A, Hong SM, Hruban RH, Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin. Cancer Res. 18(4), 981-992 (2012).
75. Liu R, Chen X, Du Y et al. Serum microRNA expression profle as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin. Chem. 58(3), 610-618 (2012).
76. Tricoli J V, Jacobson JW. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Cancer Res. 67(10), 4553-4555 (2007). (Pubitemid 46910157)
77. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008).
78. Ji B, Tsou L, Wang H et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology 137(3), 1072-1082 (2009).
79. Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 54(13), 3568-3573 (1994). (Pubitemid 24225985)
80. Parker LA, Lumbreras B, Lopez T, Hernandez-Aguado I, Porta M. How useful is it clinically to analyse the K-ras mutational status for the diagnosis of exocrine pancreatic cancer? A systematic review and meta-analysis. Eur. J. Clin. Invest. 41(7), 793-805 (2011).
81. Wang Q, Chaerkady R, Wu J et al. Mutant proteins as cancer-specifc biomarkers. Proc. Natl Acad. Sci. USA 108(6), 2444-2449 (2011).
82. Faca VM, Song KS, Wang H et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med. 5(6), e123 (2008).
83. Gruner BM, Hahne H, Mazur PK et al. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer. PLoS One 7(6), e39424 (2012).
84. Chakraborty S, Baine MJ, Sasson AR, Batra SK. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim. Biophys. Acta 1815(1), 44-64 (2011).
85. Klein A P, Brune KA, Petersen GM et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 64(7), 2634-2638 (2004). (Pubitemid 38523922)
86. McKay CJ, Glen P, McMillan DC. Chronic infammation and pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 22(1), 65-73 (2008).
87. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best. Pract. Res. Clin. Gastroenterol. 24(3), 349-358 (2010).
88. Lowenfels AB, Maisonneuve P, DiMagno EP et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J. Natl Cancer Inst. 89(6), 442-446 (1997). (Pubitemid 27136736)
89. Klein A P. Genetic susceptibility to pancreatic cancer. Mol. Carcinog. 51(1), 14-24 (2012).
90. Eckerle MD, Bishop M, Resse E, Sluzevich J. Familial atypical multiple mole melanoma syndrome. In: Cancer Syndromes. Riegert-Johnson DL, Boardman LA, Hefferon T, Roberts M (Eds). National Center for Biotechnology Information, MD, USA (2009).
91. van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz- Jeghers syndrome: a systematic review and surveillance recommendations. Am. J. Gastroenterol. 105(6), 1258-1264 (2010).
92. Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin. Gastroenterol. Hepatol. 4(4), 408-415 (2006).
93. Kastrinos F, Mukherjee B, Tayob N et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302(16), 1790-1795 (2009).
94. Geary J, Sasieni P, Houlston R et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam. Cancer 7(2), 163-172 (2008). (Pubitemid 351871910)
95. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J. Med. Genet. 42(9), 711-719 (2005). (Pubitemid 41306062)
96. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J. Natl Cancer Inst. 94(18), 1358-1365 (2002). (Pubitemid 35154140)
97. Lynch SM, Vrieling A, Lubin JH et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am. J. Epidemiol. 170(4), 403-413 (2009).
98. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas 40(3), 339-351 (2011).
99. Ishizone S, Yamauchi K, Kawa S et al. Clinical utility of quantitative RT-PCR targeted to alpha1, 4-N-acetylglucosaminyltransferase mRNA for detection of pancreatic cancer. Cancer Sci. 97(2), 119-126 (2006). (Pubitemid 43379479)
100. Kiriyama S, Hayakawa T, Kondo T et al. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer. Cancer 65(7), 1557-1561 (1990). (Pubitemid 20106115)
101. Kobayashi T, Kawa S, Tokoo M et al. Comparative study of CA-50 (time-resolved fuoroimmunoassay), Span-1, and CA19.9 in the diagnosis of pancreatic cancer. Scand. J. Gastroenterol. 26(7), 787-797 (1991).
102. Simeone DM, Ji B, Banerjee M et al. CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34(4), 436-443 (2007). (Pubitemid 46725785)
103. Koopmann J, Rosenzweig CN, Zhang Z et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19.9. Clin. Cancer Res. 12(2), 442-446 (2006). (Pubitemid 43166133)
104. Rosty C, Christa L, Kuzdzal S et al. Identifcation of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 62(6), 1868-1875 (2002). (Pubitemid 34408515)
105. Koopmann J, Fedarko NS, Jain A et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 13(3), 487-491 (2004). (Pubitemid 38737477)
106. Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J. Clin. Oncol. 24(2), 252-258 (2006). (Pubitemid 46622054)
107. Jiang JT, Wu CP, Deng HF et al. Serum level of TSGF, CA242 and CA19.9 in pancreatic cancer. World J. Gastroenterol. 10(11), 1675-1677 (2004).
108. Brand RE, Nolen BM, Zeh HJ et al. Serum biomarker panels for the detection of pancreatic cancer. Clin. Cancer Res. 17(4), 805-816 (2011).
109. Huang H, Dong X, Kang MX et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identifed by peripheral blood-based gene expression profles. Am. J. Gastroenterol. 105(7), 1661-1669 (2010).
110. Firpo MA, Gay DZ, Granger SR et al. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J. Surg. 33(4), 716-722 (2009).
111. Jiang XT, Tao HQ, Zou SC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat. Dis. Int. 3(3), 464-468 (2004).